Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ruxolitinib increases body weight in patients with primary myelofibrosis and metastatic pancreatic adenocarcinoma.
“A Phase II trial of the JAK1/2 inhibitor, ruxolitinib, has been shown to increase body weight, in patients with primary myelofibrosis (PMF) and metastatic pancreatic adenocarcinoma”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Cerchione et al., 2017
In the case description (page not available), a patient with primary myelofibrosis gained weight to 55 kg after ruxolitinib was restarted in combination with hydroxyurea. The paper is a single-patient case report, not a Phase II trial, and our copy reports no patients with metastatic pancreatic adenocarcinoma. (LLM, conf=0.90)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 9
- [1]Kralovics R Passamonti F Buser AS Teo SS Tiedt R Passweg JR Tichelli A Cazzola M Skoda RC A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 2005 352 17 1779 1790 10.1056/NEJMoa051113 15858187 · DOI · Paper page
- [2]Tefferi A Pardanani A Myeloproliferative neoplasms: a contemporary review JAMA Oncol 2015 1 1 97 105 10.1001/jamaoncol.2015.89 26182311 · DOI
- [3]Tefferi A Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management Am J Hematol 2014 89 9 915 925 10.1002/ajh.23703 25124313 · DOI
- [4]Picardi M Martinelli V Ciancia R Soscia E Morante R Sodano A Fortunato G Rotoli B Measurement of spleen volume by ultrasound scanning in patients with thrombocytosis: a prospective study Blood 2002 99 11 4228 4230 10.1182/blood.V99.11.4228 12010832 · DOI
- [5]Verstovsek S Mesa RA Gotlib J Levy RS Gupta V DiPersio JF Catalano JV Deininger MW Miller CB Silver RT Talpaz M Winton EF Harvey JH Jr Arcasoy MO Hexner EO Lyons RM Raza A Vaddi K Sun W Peng W Sandor V Kantarjian H investigators C-I Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I Haematologica 2015 100 4 479 488 10.3324/haematol.2014.115840 25616577 PMC4380721 · DOI
- [6]Vannucchi AM Kantarjian HM Kiladjian JJ Gotlib J Cervantes F Mesa RA Sarlis NJ Peng W Sandor V Gopalakrishna P Hmissi A Stalbovskaya V Gupta V Harrison C Verstovsek S Investigators C A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis Haematologica 2015 100 9 1139 1145 10.3324/haematol.2014.119545 26069290 PMC4800694 · DOI · Paper page
- [7]Al-Ali HK Griesshammer M le Coutre P Waller CF Liberati AM Schafhausen P Tavares R Giraldo P Foltz L Raanani P Gupta V Tannir B Ronco JP Ghosh J Martino B Vannucchi AM Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial Haematologica 2016 101 9 1065 1073 10.3324/haematol.2016.143677 27247324 PMC5060023 · DOI
- [8]Polverelli N Catani L Vianelli N Baccarani M Cavo M Palandri F Ruxolitinib—but not fedratinib—induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms Ann Hematol 2015 94 9 1585 1587 10.1007/s00277-015-2397-9 25975976 · DOI
- [9]Mesa RA Verstovsek S Gupta V Mascarenhas JO Atallah E Burn T Sun W Sandor V Gotlib J Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I Clin Lymphoma Myeloma Leuk 2015 15 4 214 221 e211 10.1016/j.clml.2014.12.008 25682576 PMC4418454 · DOI
Cited by
Sorted by citations
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314 · see citing works
“APhase II trial of the JAK1/ 2 inhibitor, ruxolitinib, has been shown to increase body weight, in patients with primary myelofibrosis (PMF) and metastatic pancreatic adenocarcinoma (Jatoi, 2013; Cerchione et al., 2017).”
Background
- Authors
- Cerchione, C., Peluso, I., Nappi, D., Pareto, A. E., Picardi, M., Martinelli, V., & Pane, F.
- Affiliations
- Federico II University Hospital (IT)
- Corresponding author
- Cerchione, Claudio
- Venue
- Annals of Hematology
- Published
- 2017-02-14
- Volume
- 96
- Issue
- 4
- Pages
- 697-699
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- PMC
- PMC5334413
- OpenAlex
- W2588055063
- Cited by
- 12
- References
- 0
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 4 · 2018: 6
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Annals of Hematology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- ruxolitinib, hydroxyurea, primary myelofibrosis, drug rechallenge, cachexia, transfusion requirements, splenomegaly, combination therapy
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Blood Transfusion, Cachexia, Drug Administration Schedule, Humans, Hydroxyurea, Male, Middle Aged, Nitriles, Pyrazoles, Pyrimidines, Splenomegaly, Primary Myelofibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
